Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.67 | N/A | +2.19% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.67 | N/A | +2.19% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They reiterated their commitment to navigating these challenges.
Management highlighted ongoing challenges in the current market environment.
They emphasized the importance of strategic initiatives to drive future growth.
This earnings report indicates that Protagonist Therapeutics is facing ongoing challenges, particularly reflected in their EPS results. The stock's decline of 3.48% suggests that investors are reacting cautiously to the lack of revenue information and management's defensive tone. Without updated guidance, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023